Idex Corp /De/ (IEX) Stock Analysis and Metrics

Idex

NYSE: IEX

$223.09 ▲ +0.87 (+0.39%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap16.59 Bn

P/E32.73

P/S4.70

Div. Yield0.01

ROIC (Qtr)0.11

Total Debt (Qtr)1.87 Bn

Revenue Growth (1y) (Qtr)8.92

Add ratio to table…

About

IDEX Corporation is a global applied solutions provider that delivers mission critical components for everyday life across niche markets. The company operates through more than 50 wholly owned subsidiaries that share values of trust team and excellence.

Revenue comes from the design manufacture and sale of precision fluidics positive displacement pumps sealing solutions fire fighting equipment dispensing systems and stainless steel banding. The company serves a diverse customer base that includes original equipment manufacturers industrial users municipal and water treatment facilities medical device makers semiconductor manufacturers and food and beverage processors.

The company operates through the following segments: Health & Science Technologies Fluid & Metering Technologies and Fire & Safety/Diversified Products.

• Health & Science Technologies: This segment designs produces and distributes precision fluidics positive displacement pumps powder and liquid processing technologies drying systems micro precision components pneumatic components sealing solutions high performance molded and extruded sealing components custom mechanical and shaft seals engineered hygienic mixers and valves biocompatible medical devices and implantables air compressors and blowers optical components and coatings ultra precision diamond tools laboratory and commercial equipment precision photonic solutions technical ceramics hermetic sealing products porous material structures and flow control solutions.

• Fluid & Metering Technologies: This segment designs produces and distributes positive displacement pumps valves small volume provers flow meters injectors fluid handling pump modules and provides flow monitoring and other services.

• Fire & Safety/Diversified Products: This segment designs produces and distributes firefighting pumps valves and controls rescue tools lifting bags stainless steel banding and clamping devices and precision equipment for dispensing metering and mixing colorants and paints.

IDEX holds leading positions in niche markets with each reporting unit regarded as a leader in its specific product line. The company competes on product quality design and engineering capabilities product development conformity to customer specifications quality of post sale support timeliness of delivery and effectiveness of its distribution channels. Competitors vary by product and geography and no single rival offers the full range of IDEX offerings.

The company serves a broad customer base that includes original equipment manufacturers industrial users municipal and water treatment facilities medical device makers semiconductor manufacturers automotive and aviation companies chemical producers paint dispensers and food and beverage processors. No single customer accounts for more than 3% of net sales.

Investment Thesis

▲ Bull case

IDEX Corporation is poised to benefit from durable secular tailwinds in its Health & Science Technologies (HST) segment that are underappreciated by the market, particularly in data centers, semiconductors, and space/defense applications, where customer co-engineering and long program lives create multiyear visibility. The HST backlog build, driven by 17% organic order growth and 11% organic sales growth in Q1, provides sustained revenue visibility into 2027, with management confirming that customer ramp schedules are improving forecast linearity and enabling better capital planning. This contrasts with the more cyclical and short-cycle nature of FMT and FSDP, meaning HST’s growth is less susceptible to near-term macroeconomic volatility. The company’s 8020 framework is actively reallocating capital and talent toward these high-value advantaged markets, reinforcing a flywheel effect where focused investment drives higher margins, which then fund further innovation and acquisitions in adjacent growth areas like optical switching and liquid cooling for semiconductors. Recent bolt-on acquisitions in HST, while currently below segment average margins, are expected to deliver incremental margin expansion as integration progresses and 8020 actions prune lower-value components, directly supporting the guided mid-30% to eventual 40% incremental margins (flow-through) in HST. Life sciences, though pressured by China exposure and NIH funding headwinds, remains a stable, profitable base within HST, with core fluidics and optical filters growing low single digits, and management expects growth to return as these pressures ease, adding further leverage to the segment. Capital allocation remains disciplined, with CapEx increases directed almost exclusively toward HST-led growth platforms rather than fixed assets, maintaining low capital intensity while funding innovation, and the $1.1 billion liquidity position provides ample flexibility to sustain both share repurchases ($76 million in Q1) and bolt-on M&A without compromising financial strength. The raised full-year organic growth guidance to 3%-4% (from 1%-2%) and adjusted EPS guidance increase of $0.20 to $8.35-$8.55 reflect management’s confidence in HST’s ability to drive earnings through volume leverage, productivity gains, and positive price/cost dynamics, with cash flow conversion expected to reach 100% annually as working capital investments normalize. Finally, the company’s exposure to advantaged markets like space and defense benefits from early incumbency and co-engineered solutions that create high switching costs and trusted partner status, forming a durable moat that is not yet fully priced into the stock given the market’s focus on near-term FMT/FSDP softness.

IDEX Corporation is poised to benefit from durable secular tailwinds in its Health & Science Technologies (HST) segment that are underappreciated by the market, particularly in data centers, semiconductors, and space/defense applications, where customer co-engineering and long program lives create multiyear visibility. The HST backlog build, driven by 17% organic order growth and 11% organic sales growth in Q1, provides sustained revenue visibility into 2027, with management confirming that customer ramp schedules are improving forecast linearity and enabling better capital planning. This contrasts with the more cyclical and short-cycle nature of FMT and FSDP, meaning HST’s growth is less susceptible to near-term macroeconomic volatility. The company’s 8020 framework is actively reallocating capital and talent toward these high-value advantaged markets, reinforcing a flywheel effect where focused investment drives higher margins, which then fund further innovation and acquisitions in adjacent growth areas like optical switching and liquid cooling for semiconductors. Recent bolt-on acquisitions in HST, while currently below segment average margins, are expected to deliver incremental margin expansion as integration progresses and 8020 actions prune lower-value components, directly supporting the guided mid-30% to eventual 40% incremental margins (flow-through) in HST. Life sciences, though pressured by China exposure and NIH funding headwinds, remains a stable, profitable base within HST, with core fluidics and optical filters growing low single digits, and management expects growth to return as these pressures ease, adding further leverage to the segment. Capital allocation remains disciplined, with CapEx increases directed almost exclusively toward HST-led growth platforms rather than fixed assets, maintaining low capital intensity while funding innovation, and the $1.1 billion liquidity position provides ample flexibility to sustain both share repurchases ($76 million in Q1) and bolt-on M&A without compromising financial strength. The raised full-year organic growth guidance to 3%-4% (from 1%-2%) and adjusted EPS guidance increase of $0.20 to $8.35-$8.55 reflect management’s confidence in HST’s ability to drive earnings through volume leverage, productivity gains, and positive price/cost dynamics, with cash flow conversion expected to reach 100% annually as working capital investments normalize. Finally, the company’s exposure to advantaged markets like space and defense benefits from early incumbency and co-engineered solutions that create high switching costs and trusted partner status, forming a durable moat that is not yet fully priced into the stock given the market’s focus on near-term FMT/FSDP softness.

▼ Bear case

IDEX Corporation faces significant near-term headwinds in its Fluid & Metering Technologies (FMT) and Fire & Safety/Diversified Products (FSDP) segments that the market may be underestimating due to overreliance on HST strength, with FMT showing only 2% organic sales growth despite 9% organic order growth, indicating a persistent disconnect between orders and revenue recognition likely tied to project timing, customer destocking, or extended lead times in industrial end markets. FSDP’s organic sales declined 1% year-over-year, with Fire & Safety growth offset by a continued decline in dispensing due to tough comps and project timing in North America and Asia, and management explicitly cited ongoing mixed order trends and a cautious outlook for both segments due to persistent macroeconomic and geopolitical uncertainties, suggesting that the flat outlook for FMT and FSDP is not merely conservative but reflective of structural weakness in general industrial and chemical end markets. The company’s adjusted gross margin declined 40 basis points year-over-year to 44.9%, revealing that productivity gains and volume leverage are being more than offset by unfavorable mix, particularly as lower-margin acquired businesses in HST dilute overall profitability, and while HST margin expanded 100 basis points, FMT margin declined 10 basis points and FSDP margin increased only 30 basis points, highlighting uneven performance across the portfolio. Free cash flow of $86 million was $5 million below last year, driven by higher working capital investment amid growth, and the low free cash flow conversion of 58% in Q1 (vs. 69% prior year) raises concerns about earnings quality, especially since the company’s expectation of 100% annual conversion depends on working capital normalizing—a assumption that may not hold if inventory buildup or receivables growth persists due to slower sales conversion in FMT and FSDP. Although CapEx is increasing to support HST growth, the company acknowledged that recent bolt-on acquisitions have not yet achieved average segment margins, and the path to margin improvement relies on uncertain 8020 portfolio actions and life sciences recovery, meaning that incremental margin expansion in HST is not guaranteed and could be delayed if integration challenges persist or if advantaged market demand fails to materialize as expected. Finally, while management downplays tariff impacts, stating new tariffs are consistent with repealed ones and seeking IEEPA refunds, the ongoing global trade policy uncertainty and potential for future cost inflation could force unplanned price actions or margin pressure if cost inflation accelerates, especially given that price/cost was only a net positive at the EBITDA level in Q1 and not to the magnitude seen in prior quarters, leaving the company vulnerable to margin compression if input costs rise without corresponding pricing power.

IDEX Corporation faces significant near-term headwinds in its Fluid & Metering Technologies (FMT) and Fire & Safety/Diversified Products (FSDP) segments that the market may be underestimating due to overreliance on HST strength, with FMT showing only 2% organic sales growth despite 9% organic order growth, indicating a persistent disconnect between orders and revenue recognition likely tied to project timing, customer destocking, or extended lead times in industrial end markets. FSDP’s organic sales declined 1% year-over-year, with Fire & Safety growth offset by a continued decline in dispensing due to tough comps and project timing in North America and Asia, and management explicitly cited ongoing mixed order trends and a cautious outlook for both segments due to persistent macroeconomic and geopolitical uncertainties, suggesting that the flat outlook for FMT and FSDP is not merely conservative but reflective of structural weakness in general industrial and chemical end markets. The company’s adjusted gross margin declined 40 basis points year-over-year to 44.9%, revealing that productivity gains and volume leverage are being more than offset by unfavorable mix, particularly as lower-margin acquired businesses in HST dilute overall profitability, and while HST margin expanded 100 basis points, FMT margin declined 10 basis points and FSDP margin increased only 30 basis points, highlighting uneven performance across the portfolio. Free cash flow of $86 million was $5 million below last year, driven by higher working capital investment amid growth, and the low free cash flow conversion of 58% in Q1 (vs. 69% prior year) raises concerns about earnings quality, especially since the company’s expectation of 100% annual conversion depends on working capital normalizing—a assumption that may not hold if inventory buildup or receivables growth persists due to slower sales conversion in FMT and FSDP. Although CapEx is increasing to support HST growth, the company acknowledged that recent bolt-on acquisitions have not yet achieved average segment margins, and the path to margin improvement relies on uncertain 8020 portfolio actions and life sciences recovery, meaning that incremental margin expansion in HST is not guaranteed and could be delayed if integration challenges persist or if advantaged market demand fails to materialize as expected. Finally, while management downplays tariff impacts, stating new tariffs are consistent with repealed ones and seeking IEEPA refunds, the ongoing global trade policy uncertainty and potential for future cost inflation could force unplanned price actions or margin pressure if cost inflation accelerates, especially given that price/cost was only a net positive at the EBITDA level in Q1 and not to the magnitude seen in prior quarters, leaving the company vulnerable to margin compression if input costs rise without corresponding pricing power.

Business Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Specialty Industrial Machinery

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEV	GE Vernova Inc.	270.93 Bn	28.46	6.55	2.79 Bn
2	ETN	Eaton Corp plc	156.55 Bn	39.19	5.50	21.05 Bn
3	PH	Parker-Hannifin Corp	124.04 Bn	35.64	5.91	9.58 Bn
4	CMI	Cummins Inc	91.66 Bn	34.29	2.70	6.89 Bn
5	EMR	Emerson Electric Co	82.90 Bn	67.34	4.53	13.36 Bn
6	ITW	Illinois Tool Works Inc	81.54 Bn	26.02	5.03	9.15 Bn
7	AME	Ametek Inc/	55.40 Bn	36.26	7.29	2.18 Bn
8	ROK	Rockwell Automation, Inc	51.78 Bn	53.05	5.88	3.69 Bn

Research Tools

Developers

About

Investment Thesis

Business Segments Breakdown of Revenue (2025)

Business Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Business Segments Breakdown of Revenue (2025)

Business Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password